01—Abstract
Summary
Summary of the 10-Q filed February 6, 2025. Cited figures are marked; the original filing is the authoritative source.
McKesson Corporation reported strong revenue growth for the third quarter and first nine months of fiscal year 2025, driven by its U.S. Pharmaceutical segment and increased volumes in its International segment.
Diluted Earnings Per Share (EPS) saw a significant increase in the third quarter, though it slightly declined year-over-year for the nine-month period. The company also completed the divestiture of its Canadian retail businesses. Significant charges related to restructuring initiatives and remeasuring the Canadian retail disposal group to fair value were incurred.
McKesson continues to manage its substantial opioid-related litigation liabilities, with significant payments made and a large accrued liability remaining. The company's financial position remains solid, supported by robust operating cash flow and access to credit facilities. McKesson continues to return capital to shareholders through dividends and substantial share repurchases, with a significant remaining authorization.
Strategic acquisitions, including a controlling interest in PRISM Vision Holdings, are underway to further enhance its business segments. Investors should monitor ongoing litigation developments, particularly those related to opioids, and the integration of new acquisitions.
02—Key points
Key Highlights
- Revenue increased by 18% to $95.3 billion for the three months ended December 31, 2024, and by 15% to $268.2 billion for the nine months ended December 31, 2024.
- Diluted EPS increased to $6.95 for the three months ended December 31, 2024, up from $4.42 in the prior year period.
- Completed the sale of its Canadian retail businesses (Rexall and Well.ca) on December 30, 2024.
- Incurred $666 million in charges related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell for the nine-month period.
- Recorded $213 million in restructuring, impairment, and related charges for the nine-month period, related to enterprise-wide initiatives.
- Total estimated opioid-related litigation liabilities stood at $6.4 billion as of December 31, 2024.
- Returned $3.1 billion to shareholders through $2.8 billion in share repurchases and $254 million in dividends during the nine months ended December 31, 2024.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, McKesson Corp kept $0.01.
- Revenue$95.29B100.0%
- Cost of revenue−$92.01B96.6%
- Gross profit$3.28B3.4%
- Operating costs−$2.06B2.2%
- Operating income$1.22B1.3%
- Interest, other & tax−$345.0M0.4%
- Net income$879.0M0.9%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed February 6, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $95.29B$80.90B | +17.8% |
| Cost of Revenue | $92.01B$77.75B | +18.3% |
| Gross Profit | $3.28B$3.15B | +4.2% |
| SG&A Expenses | $2.03B$2.51B | −19.1% |
| Operating Expenses | $2.06B$2.51B | −17.9% |
| Operating Income | $1.22B$642.00M | +90.7% |
| Interest Expense | $67.00M$64.00M | +4.7% |
| Net Income | $879.00M$589.00M | +49.2% |
| EPS (Basic) | $6.98$4.45 | +56.9% |
| EPS (Diluted) | $6.95$4.42 | +57.2% |
| Shares Outstanding (Basic) | 126.00M132.50M | −4.9% |
| Shares Outstanding (Diluted) | 126.60M133.30M | −5.0% |
05—Questions
Frequently Asked Questions
What were the primary drivers of McKesson's revenue growth in this quarter?
Revenue growth was primarily driven by market expansion in the U.S. Pharmaceutical segment, including higher volumes from retail national account customers and growth in specialty pharmaceuticals. The International segment also contributed with higher pharmaceutical distribution volumes.
How is McKesson managing its opioid litigation liabilities?
McKesson has entered into settlement agreements with numerous states, subdivisions, and Native American tribes, totaling approximately $2.0 billion paid to date under a broad settlement, with future payments through 2038. The company has also settled claims with Alabama and West Virginia subdivisions. The total estimated liability for opioid-related claims was $6.4 billion as of December 31, 2024.
What is the outlook for McKesson's share repurchase program?
McKesson's Board of Directors has authorized a significant share repurchase program. In July 2024, they approved an increase of $4.0 billion, bringing the total remaining authorization to $7.8 billion as of December 31, 2024. The company actively repurchased shares throughout the reported periods.
Are there any significant acquisitions or divestitures impacting the company?
Yes, McKesson completed the sale of its Canadian retail businesses (Rexall and Well.ca) on December 30, 2024. Additionally, the company announced an agreement to acquire a controlling interest in PRISM Vision Holdings for approximately $850 million, which is expected to be reported within the U.S. Pharmaceutical segment upon completion.
06—Continue